Education
About Us
Working with TipRanks
Follow Us
IN8bio (INAB)
NASDAQ:INAB
INAB Stock Chart & Stats
$1.21
-$0.04(-11.59%)
At close: 4:00 PM EST
$1.21
-$0.04(-11.59%)
Day’s Range― - ―
52-Week Range$1.53 - $12.54
Previous CloseN/A
Volume363.43K
Average Volume (3M)74.58K
Market Cap
$5.61M
Enterprise Value-$1.50M
Total Cash (Recent Filing)$10.69M
Total Debt (Recent Filing)$2.96M
Price to Earnings (P/E)―
Beta1.64
Next Earnings
Mar 12, 2026EPS Estimate
-0.74Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.85
Shares Outstanding4,634,396
10 Day Avg. Volume64,995
30 Day Avg. Volume74,576
Financial Highlights & Ratios
PEG Ratio0.32
Price to Book (P/B)28.55
Price to Sales (P/S)0.00
P/FCF Ratio-17.04
Enterprise Value/Market Cap-0.27
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda0.08
Forecast
1Y Price Target
$4.00Price Target Upside230.58% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical Trial SuccessMultiple doses of INB-200 showed mPFS of 16.1 months, beating historical benchmarks of 6.2 months and 10.3 months in GBM patients with unmethylated or methylated MGMT promoter, respectively.
Preclinical DataIN8bio presented promising preclinical data with their CD19 targeting γδ TCE (INB-619) showing deep B cell depletion in lupus patient blood samples.
Safety ProfileNo new safety concerns were reported. No DLT, ICANS, CRS, or DRI-.
Bears Say
Clinical Trial SuspensionIN8bio suspended enrollment in their clinical trials evaluating INB-200 and '400 in GBM last year, and is actively exploring strategic partnerships and other potential opportunities to further develop this program.
Financial OutlookFollowing the reverse split announced, the share counts were adjusted in the valuation model, resulting in a new price target of $3.
Partnership ExplorationManagement is exploring partnership and collaboration options to further develop the program.
IN8bio News
INAB FAQ
What was IN8bio’s price range in the past 12 months?
IN8bio lowest stock price was $1.53 and its highest was $12.54 in the past 12 months.
What is IN8bio’s market cap?
IN8bio’s market cap is $5.61M.
When is IN8bio’s upcoming earnings report date?
IN8bio’s upcoming earnings report date is Mar 12, 2026 which is in 81 days.
How were IN8bio’s earnings last quarter?
IN8bio released its earnings results on Nov 06, 2025. The company reported -$0.85 earnings per share for the quarter, beating the consensus estimate of -$1.084 by $0.234.
Is IN8bio overvalued?
According to Wall Street analysts IN8bio’s price is currently Undervalued.
Does IN8bio pay dividends?
IN8bio does not currently pay dividends.
What is IN8bio’s EPS estimate?
IN8bio’s EPS estimate is -0.74.
How many shares outstanding does IN8bio have?
IN8bio has 4,634,396 shares outstanding.
What happened to IN8bio’s price movement after its last earnings report?
IN8bio reported an EPS of -$0.85 in its last earnings report, beating expectations of -$1.084. Following the earnings report the stock price went down -6.627%.
Which hedge fund is a major shareholder of IN8bio?
Currently, no hedge funds are holding shares in INAB
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
IN8bio
IN8bio, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of gamma-delta T cell therapies for the treatment of cancers. Its lead product candidate includes INB-200, a genetically modified autologous gamma-delta T cell product candidate that is in Phase I clinical trial for the treatment of glioblastoma and solid tumors; and INB-100, an allogeneic product candidate, which is in Phase I clinical trial to treat patients with acute leukemia undergoing hematopoietic stem cell transplantation. It also develops INB-400 and INB-300 that is in preclinical Phase for treatment of various solid tumor cancers. The company was formerly known as Incysus Therapeutics, Inc. and changed its name to IN8bio, Inc. in August 2020. IN8bio, Inc. was incorporated in 2016 and is headquartered in New York, New York.
INAB Stock 12 Month Forecast
Average Price Target
$4.00
▲(230.58% Upside)
Technical Analysis
Eterna Therapeutics
―
Quoin Pharmaceuticals
―
Xenetic Biosciences
―
VYNE Therapeutics
―
Aprea Therapeutics
―